Typically, endocrine agents are applied to ERα-positive breast cancer comprised of selective ER modulators (SERMs), selective ER degraders (SERDs), and aromatase inhibitors (AI), which are committed to regional recurrence suppression and long-term survival benefit. This evidence concerns the gene ESR1 and breast cancer.